deCODE Initiates Chemical Development Collaboration with SGX
News Jun 15, 2007
deCODE chemistry has initiated a new chemical development service collaboration with SGX Pharmaceuticals. The research performed by deCODE chemistry is aimed at developing and executing a scalable production process for SGX.
Under this collaboration SGX will gain access to deCODE’s platform for chemical development including route optimization, production of toxicology lots, cGMP production of clinical batches, physical form characterization, and all associated analytical method development and validation.
“We are pleased that SGX Pharmaceuticals chose the deCODE chemistry team for their chemical development needs,” said Dr. David Zembower, Vice President of Chemistry at deCODE. “Over the years we have continued to build upon our service platform to provide our valued clients with a rapid, cost-effective transition from selection of development candidates through entry into human clinical trials.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE